Generic Diastat Availability
Last updated on Jun 11, 2025.
See also: Generic Diastat AcuDial
Diastat is a brand name of diazepam, approved by the FDA in the following formulation(s):
DIASTAT (diazepam - gel;rectal)
-
Manufacturer: BAUSCH
Approval date: July 29, 1997
Strength(s): 2.5MG/0.5ML (5MG/ML) [RLD], 5MG/ML (5MG/ML) (discontinued) [RLD], 10MG/2ML (5MG/ML) (discontinued) [RLD], 15MG/3ML (5MG/ML) (discontinued) [RLD], 20MG/4ML (5MG/ML) (discontinued) [RLD]
Is there a generic version of Diastat available?
An Authorized Generic version of Diastat has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Diazepam RECTAL GEL 2.5 mg/.5mL
Oceanside Pharmaceuticals
NDC Code: 686820650 - diazepam RECTAL GEL 10 mg/2mL
Oceanside Pharmaceuticals
NDC Code: 686820652 - Diazepam RECTAL GEL 20 mg/4mL
Oceanside Pharmaceuticals
NDC Code: 686820655 - diazepam RECTAL GEL 10 mg/2mL
Bryant Ranch Prepack
NDC Code: 721621900
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Diastat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Diastat (diazepam)
- Check interactions
- Compare alternatives
- Reviews (2)
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: benzodiazepine anticonvulsants
- Breastfeeding
Patient resources
Other brands
Valium, Valtoco, Diazepam Intensol, Libervant, Zetran
Professional resources
Other brands
Other formulations
Related treatment guides
Related/similar drugs
Lamictal
Lamictal is an anti-epileptic medication used treat seizures in adults and children over 2 years ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Keppra
Keppra is an anti-epileptic drug used to treat partial onset seizures in people with epilepsy ...
Carbamazepine
Carbamazepine is used to treat epileptic seizures and nerve pain such as trigeminal neuralgia ...
Levetiracetam
Levetiracetam is used for bipolar disorder, epilepsy, hyperekplexia, neuralgia, new daily ...
Lyrica
Lyrica is used to control seizures, treat nerve pain and fibromyalgia. Learn about side effects ...
Topiramate
Learn about topiramate, an anticonvulsant used for seizures, migraine prevention, and weight loss ...
Pregabalin
Pregabalin may be used to treat certain types of pain and used in combination with other ...
Lamotrigine
Lamotrigine is an anti-epileptic medication used for seizures in adults and children over 2 years ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.